Cargando…
Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants
Available CFTR modulators provide no therapeutic benefit for cystic fibrosis (CF) caused by many loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, including N1303K. We previously introduced the concept of ‘co-potentiators’ (combination-pot...
Autores principales: | Phuan, Puay-Wah, Tan, Joseph-Anthony, Rivera, Amber A., Zlock, Lorna, Nielson, Dennis W., Finkbeiner, Walter E., Haggie, Peter M., Verkman, Alan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881293/ https://www.ncbi.nlm.nih.gov/pubmed/31776420 http://dx.doi.org/10.1038/s41598-019-54158-2 |
Ejemplares similares
-
CFTR Activator Increases Intestinal Fluid Secretion and Normalizes Stool Output in a Mouse Model of Constipation
por: Cil, Onur, et al.
Publicado: (2016) -
Potential Therapeutic Benefit of C1-Esterase Inhibitor in Neuromyelitis Optica Evaluated In Vitro and in an Experimental Rat Model
por: Tradtrantip, Lukmanee, et al.
Publicado: (2014) -
CFTR-Adenylyl Cyclase I Association Responsible for UTP Activation of CFTR in Well-Differentiated Primary Human Bronchial Cell Cultures
por: Namkung, Wan, et al.
Publicado: (2010) -
Anticancer metallohelices: nanomolar potency and high selectivity
por: Kaner, Rebecca A., et al.
Publicado: (2016) -
Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
por: Armirotti, Andrea, et al.
Publicado: (2019)